Since none of these stage II and all of the stage III colon cancer patients received 5-fluorouracil (5-FU)-based adjuvant chemotherapy, it is not possible to discern whether APC mutations confer resistance to adjuvant chemotherapy or whether this difference in prognosis is due to effects of APC mutations on biology of cancer cells that metastasize to the lymph nodes. This evidence concerns the gene APC and colonic neoplasm.